Novartis (NVS) Alert: Johnson Fistel Launches Investigation into Novartis AG; Investors Encouraged to Contact Firm

Thursday, August 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Novartis AG ("Novartis") (NYSE: NVS) for violations of federal securities laws.

On August 7, 2019, Novartis made known that it knew about discrepancies in data it submitted to regulators as it sought approval

of its gene therapy drug Zolgensma, but delayed notifying authorities until it completed an internal investigation.

Novartis faces possible penalties from the FDA. On August 6, 2019, the FDA said the company was aware of the problems for as much as two months before the drug's U.S. approval.

If you recently purchased Novartis and lost money, realized or unrealized on your investment, and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:Johnson Fistel, LLPJim Baker, 619-814-4471jimb@johnsonfistel.com

[click here to join this action]

Cision View original content:http://www.prnewswire.com/news-releases/novartis-nvs-alert-johnson-fistel-launches-investigation-into-novartis-ag-investors-encouraged-to-contact-firm-300898453.html

SOURCE Johnson Fistel, LLP



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store